Dual Incretin-Receptor Signaling
Studied for simultaneous agonist activity at GIP and GLP-1 receptors in experimental metabolic-signaling models.
Overview
SRX-21 (TR) is a dual GIP/GLP-1 receptor agonist studied for its combined engagement of two incretin pathways implicated in glucose and energy regulation.
Suria's SRX-21 (TR) is offered for laboratory research, with batch-specific analytical documentation made available through Suria's Batch Documentation system for applicable tested batches.
Research Use Only. Not for human or veterinary use.
Specifications
Certificate of Analysis
Certificate of Analysis
SRX-21 (TR) is not currently available for purchase. A certificate is published when a lot is released for sale.
Research Highlights
Studied for simultaneous agonist activity at GIP and GLP-1 receptors in experimental metabolic-signaling models.
Used to investigate the combined pharmacology of two incretin-receptor pathways within a single molecule.
Extensively characterized in preclinical and clinical literature examining dual GIP/GLP-1 receptor agonism.
Consistent, well-documented starting material for pathway and concentration-response studies.
Storage
Store at −20°C, protected from light and moisture, until ready for reconstitution.
Store at 2–8°C and use within the laboratory's established handling window.
Avoid repeated freeze-thaw cycles to help preserve peptide integrity across a research protocol.
Research Use Only. Not for human consumption.
Frequently Asked Questions
Batch Documentation